Ferroptosis-Related Long Non-Coding RNA signature predicts the prognosis of Head and neck squamous cell carcinoma

Yun Tang, MD; Cheng Li, MD; You-Jing Zhang, MD; Zeng-Hong Wu, MD

1. Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
2. Department of Otolaryngology Head and Neck Surgery, The Central Hospital of Wuhan, Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China.
3. School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
4. Department of Otolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
5. Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

Corresponding author: Zeng-Hong Wu, Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China (Email: D201981596@hust.edu.cn).

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).
See http://ivyspring.com/terms for full terms and conditions.

Received: 2020.11.06; Accepted: 2021.01.12; Published: 2021.01.31

Abstract

Background: Head and neck squamous cell carcinoma (HNSCC) are head and neck cancers. On the other hand, ferroptosis is a novel iron-dependent and ROS reliant type of cell death observed various disease conditions.

Method: We constructed a prognostic multilncRNA signature based on ferroptosis-related differentially expressed IncRNAs in HNSCC.

Results: We identified 25 differently expressed IncRNAs associated with prognosis of HNSCC. Kaplan-Meier analyses revealed the high-risk IncRNAs signature associated with poor prognosis of HNSCC. Moreover, the AUC of the IncRNAs signature was 0.782, underscoring their utility in prediction HNSCC prognosis. Indeed, our risk assessment model was superior to traditional clinicopathological features in predicting HNSCC prognosis. GSEA revealed the immune and tumor-related pathways in the low risk group individuals. Moreover, TCGA revealed T cell functions including cytolytic activity, HLA, regulation of inflammation, co-stimulation, co-inhibition and coordination of type II INF response were significantly different between the low-risk and high-risk groups. Immune checkpoints such as PDCD-1 (PD-1), CTLA4 and LAG3, were also expressed differently between the two risk groups.

Conclusion: A novel ferroptosis-related IncRNAs signature impacts on the prognosis of HNSCC.

Key words: Head and neck squamous cell carcinoma, ferroptosis, genes, IncRNAs, immune infiltration, data mining.

Introduction

Head and neck squamous cell carcinoma (HNSCC) are neoplasms affecting different tissues and organs in the head and neck region including the tongue, mouth, nasopharynx, larynx and throat [1]. Every year, there are over 655,000 new HNSCC cases (globally), resulting in 90,000 deaths [2]. Tobacco smoking, alcohol consumption and human papillomavirus (HPV) infection are important risk factors for developing HNSCC [3]. Moreover, Epstein-Barr virus (EBV) is strongly associated with nasopharyngeal carcinoma (NPC) [4]. Although several treatment options such as surgery, radiotherapy and chemotherapy are available, the asymptomatic nature and lack of early detection of HNSCC result in less than 50% 5-year survival rate of individuals with the cancers. In addition, due to the same reasons, even after treatment, the risk of recurrence and metastasis of HNSCC remain high [5, 6]. Efficient clinical management of HNSCC has been constrained by suboptimal preclinical models or lack
of accurate biomarkers for early diagnosis of the cancers. Currently, there are several anti-tumor drugs that induce apoptosis of cancer cells [7]. Thus, it is particularly critical to explore other forms of cell death to overcome tumor cell resistance while at the same time uncovering new and efficient prognostic biomarkers for HNSCC.

Past decades have seen a rapid increase in research on tumor ferroptosis. This is an iron-dependent cell death reliant on intracellular accumulation of reactive oxygen species (ROS), distinct from apoptosis and autophagy [8]. Dysregulation of iron metabolism is a risk factor for cancer and as well promotes tumor growth. Compared with normal cells, cancer cells exhibit iron addiction, which is the over dependence on iron for proliferation [9]. Indeed, activation of ferroptosis pathways may override drug resistance experienced by current chemotherapeutic agents, opening a new therapeutic frontier for cancer treatment. Meanwhile, long non-coding RNAs (lncRNA) are a subset of RNA molecule about 200 nt, which regulate the expression of genes [10]. Apart from gene regulation, lncRNA participates in various biological regulatory processes, including those implicated for occurrence, development and metastasis of tumors [11]. At the moment, there are very few studies on ferroptosis-related lncRNAs. One recent study revealed that IncRNA LINC00618 is under-expressed in human leukemia cells. The mRNA promotes ferroptosis by increasing the levels of lipid ROS and iron, while decreasing the expression of SLC7A11. It further induces vincristine-induced ferroptosis and apoptosis of [12]. In a related study, Lu et al. [13] found that in acute ischemic stroke, IncRNA PVT1 regulated ferroptosis via miR-214, which modulates the expression of TFR1 and TP53. Similarly, silencing IncRNA ZFAS1 attenuated ferroptosis and significantly modulated inflammation and lipid peroxidation [14]. However, sequence-based studies that systematically evaluate ferroptosis-related IncRNA signature and its association with overall survival (OS) in HNSCC patients remain scanty. In this study, we first constructed a prognostic multi-lncRNA signature of differentially expressed ferroptosis-related IncRNA based on the Cancer Genome Atlas (TCGA) data. We then explored the role of ferroptosis-related mRNA, N6-methyladenosine (m6A) mRNA statues and immune responses in HNSCC prognosis.

Methods

Data collection

RNA-sequence (42 normal and 487 tumor) data of 511 patients was extracted from the TCGA-HNSCC database. The clinical characteristics of the patients are shown in Table 1. The corresponding ferroptosis-related genes were downloaded from FerrDb [15], a web-based consortium that provided a comprehensive and up-to-date database for ferroptosis markers, their regulatory molecules and associated diseases. Overall, we identified 259 (Driver: 108; suppressor: 69; marker: 111) ferroptosis-related genes (Table S1). The relationship between the ferroptosis-related IncRNAs and HNSCC was assessed using Pearson correlation. The association was considered significant if the correlation coefficient \( R^2 \geq 0.3 \) at \( P < 0.001 \). The collected clinical-pathological data of the HNSCC patients included gender, age, stage, grade, TMN, survival status and survival time. Significant differential expression of ferroptosis-related IncRNAs was set at FDR<0.05 and \(|\log FC| \geq 1\). First, we explored the function of both upregulated and downregulated ferroptosis-related differentially expressed genes (DEGs). We then used Gene ontology (GO) to evaluate the biological pathways associated with the DEGs. Further function analysis of biological processes (BP), molecular functions (MF) and cellular components (CC) regulated by the differently expressed ferroptosis-related IncRNAs were analyzed based on Kyoto Encyclopedia of Genes and Genomes (KEGG) data using R software, ggplot2 package.

Table 1. The clinical characteristics of patients in the TCGA dataset.

| Variable                  | Number of samples |
|---------------------------|-------------------|
| Gender                    | 374/137           |
| Male/Female               |                   |
| Age at diagnosis ≤65/>65/NA| 336/174/1         |
| Grade                     | 60/305/118/7/23   |
| G1/G2/G3/G4/NA            |                   |
| Stage                     | 27/75/81/256/72   |
| 1/II/III/IV/NA            |                   |
| T0/T1/T2/T3/T4/NA         | 1/49/140/99/161/61|
| M                         | 184/1/326         |
| M0/M1/NA                  |                   |
| N                         | 172/67/167/18/97  |
| N0/N1/N2/N3/NA            |                   |

Development of the ferroptosis-related lncRNAs prognostic signature

We used Lasso-penalized Cox regression and Univariate Cox regression analyses to construct the ferroptosis-related lncRNAs signature, stratified based on risk score (Coefficient IncRNA1 × expression of IncRNA1) + (Coefficient IncRNA2 × expression of IncRNA2) + · · · + (Coefficient IncRNA n × expression IncRNA n). The associated risk score for each HNSCC patients were also evaluated. The RNAs were classified in either low-risk (<median number) or
high-risk (≥ median number) group based on the median score.

**The predictive nomogram**

We performed Gene set enrichment analyses (GSEA) to define the lncRNAs signatures in the KEGG, which were then searched in the TCGA-HNSCC database. Statistical significance was set at \( P < 0.05 \) and false discovery rate (FDR) \( q < 0.25 \). A nomogram was constructed integrating the prognostic signatures, for predictive of 1, 3, and 5-year OS of HNSCC patients.

**Immunity analysis and gene expression**

At the same time, the CIBERSORT [16, 17], ESTIMATE [18], MCPcounter [19], single-sample gene set enrichment analysis (ssGSEA) [20] and TIMER [21] algorithms were compared to assess cellular components or cell immune responses between high risk and low risk group based on ferroptosis-related lncRNAs signature. The differences in immune response under different algorithms were uncovered using a Heatmap. In addition, ssGSEA was used to quantify the tumor-infiltrating immune cell subgroups between the two groups as well as assessing their immune function. Potential immune checkpoint was also retrieved from previous literature.

**Statistical analysis**

Data was analyzed using Bioconductor packages in R software, version 4.0.2. Normally and non-normally distributed variables were analyzed using the unpaired student's t-test and the Wilcoxon test, respectively. Benjamini-Hochberg method was used to identify the differently expressed lncRNAs, based on FDR. The ssGSEA-normalized HNSCC DEGs were compared with a genome using "GSVA" (R-package). The sensitivity and specificity of the derive prognostic signatures for HNSCC in comparison to other clinicopathological was assessed using the operating characteristic curve (ROC) and decision curve analysis (DCA) [22]. The relationship between ferroptosis-related lncRNAs and clinicopathological manifestations was evaluated using logistic regression analyses and a heatmap graph. The survival analysis of HNSCC patients based on the ferroptosis-related lncRNAs signature was assessed using the Kaplan–Meier survival analysis. For each analysis, statistical significance was set at \( P < 0.05 \).

**Results**

**Enrichment Analysis of ferroptosis-related genes**

We uncovered 65 ferroptosis-related DEGs (18 downregulated and 47 upregulated; Table S2). BP participated in the production of oxidative stress superoxide anion, homeostasis and metabolism of superoxides among others. MF mainly regulated production of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, molecular oxygen and binding of ferric iron. CC were mainly up-regulated in NADPH oxidase complex, oxidoreductase complex and apical plasma membrane synthesis pathways. KEGG based analysis revealed the over-expressed genes were mainly involved in ferroptosis, hypoxia-inducible factor (HIF)-1 signaling pathway, synthesis of microRNAs in cancer cells, IL-17 signaling pathway, central carbon metabolism in cancer cells, bladder cancer, human cytomegalovirus infection and mTOR signaling pathway (Figure 1 and Table S3).

**The ferroptosis-based lncRNAs prognostic signature**

We uncovered 935 ferroptosis-related lncRNAs (Table S4). Univariate COX analysis identified 75 significant ferroptosis-related lncRNAs, which were included in the multivariate COX analysis. Overall, 25 differently expressed lncRNAs (LINC01963, AL357033.4, LIN01980, AL329898.1, AATBC, ELF3-AS1, AC135030.6, AL161431.1, AC106820.3, AL451085.2, AC007991.2, AC136475.1, AC012467.2, AC144631.1, AC116914.2, AC008115.3, PSMA3-AS1, PCED1B-AS1, AL139158.2, EP300-AS1, AC104083.1, AL022328.2, AC012640.2, PAX8-AS1, and AL450992.2) were found to be independent prognosis predictors of HNSCC (Table S5). Thus, we calculated risk scores and constructed a prognostic signature for the lncRNAs.

**Survival results and multivariate examination**

Kaplan-Meier analyses revealed the expression of high-risk lncRNAs signatures corresponded with poorer survival (\( P<0.001 \), Figure 2A). Meanwhile, the AUC of the signature lncRNAs was 0.782, exhibiting superior performance than the traditional clinicopathological features in predicting the prognosis of HNSCC (Figure 2B, 2E). Using patient's risk survival status plot, we found the patient's risk score was inversely proportional to the survival of patients with HNSCC. Interestingly, our heatmap demonstrated that most of the novel lncRNAs uncovered in this study were negative correlation with our risk model and needs more researches to conduct (Figure 2C). The AUC predictive value of the novel lncRNAs signature for 1, 3, 5-year survival rate was 0.78, 0.83 and 0.71, respectively (Figures 2D). Univariate and multivariate COX analysis revealed that lncRNAs signature (HR: 1.38, 95CI: 1.25-1.51) as
well as tumor stage (HR: 1.88, 95CI: 1.28-2.76) were independent prognosis factors of OS of HNSCC patients (Figure 3A, 3B). The relationship between lncRNA and mRNA is shown in Figure 3C. The heatmap for the association between ferroptosis-related lncRNAs prognostic signature and clinicopathological manifestations were also analyzed (Figure 4). The hybrid nomogram incorporating clinicopathological characteristics and the novel ferroptosis-related lncRNAs prognostic signature (Figure 5) was stable and accurate, thus may be applied in clinical management of HNSCC patients.

**Gene set enrichment analyses**

Gene set enrichment analyses (GSEA) revealed the majority of the novel ferroptosis-related lncRNAs prognostic signature regulated immune and tumor-related pathways such as primary immunodeficiency, natural killer cell mediated cytotoxicity, T/B cell receptor signaling pathway, FC gamma R mediated phagocytosis, homologous recombination, notch signaling pathway, acute myeloid leukemia, colorectal cancer, and jak stat signaling pathway (Figure 6) and (Table S6).
Immunity and gene expression

The heatmap of immune responses based on CIBERSORT, ESTIMATE, MCP counter, single-sample gene set enrichment analysis (ssGSEA) and TIMER algorithms is shown in Figure 7. Correlation analysis between immune cell subpopulations and related functions based on ssGSEA of TCGA-HNSCC data revealed that T cell functions including checkpoint (inhibition), cytolytic, HLA, regulation of inflammation, co-stimulation of, co-inhibition of and type II INF response were significantly different between the low-risk and high-risk groups Figure 8A. Given the importance of checkpoint inhibitor-based immunotherapies, we further explored the difference in the expression of immune checkpoints between the two groups. We found a substantial difference in the expression of PDCD-1 (PD-1), CTLA4, LAG3, BTLA among others, between the two groups of patients (Figure 8B). The comparison in the expression of m6A-related mRNA expression between high and low risk group
suggested that the expression of RBM15, YTHDC1, and TDHDC2 were significance (Figure 9).

**Discussion**

Ferroptosis can overcome resistance of malignant cells to chemotherapy and as well facilitate removal of defective cells. As such, it’s potentially a novel approach for tumor treatment. In this study, we first identified novel ferroptosis-related prognostic lncRNAs signature based on the TCGA dataset. We then explored the roles of immune infiltrating cells in tumor microenvironment and immune checkpoint inhibitors in the prognosis of HNSCC. Findings of this study uncovered potential biomarker and therapeutic target in the ferroptosis signaling pathways.

![Figure 5. A nomogram for both clinic-pathological factors and prognostic ferroptosis-related lncRNAs.](image)

![Figure 6. Gene enrichment analysis for ferroptosis-related lncRNAs based on TCGA.](image)
Figure 7. Heatmap for immune responses based on CIBERSORT, ESTIMATE, MCPcounter, ssGSEA, and TIMER algorithms among high and low risk group.

Figure 8. (A). ssGSEA for the association between immune cell subpopulations and related functions (B). Expression of immune checkpoints among high and low HNSCC risk groups.
Overall, our analyses uncovered 65 ferroptosis-related DEGs. KEGG analyses further revealed the genes mainly participated in hypoxia-inducible factor (HIF)-1 signaling pathway, expression of cancer related microRNAs, IL-17 signaling pathway, central carbon metabolism in cancer cells and mTOR signaling pathway. A recent study found that FG-4592 (an inhibitor of prolyl hydroxylase of HIF) pretreatment reduces ferroptosis in advanced stage of kidney injury by activating Nrf2 via the Akt/GSK-3β-mediated [24]. Takahashi et al. [25] reported that cancer spheroids utilize the mammalian target of rapamycin (mTOR) for proliferation and the lipid peroxidase GPX4 for defense against ferroptosis. Overall, in this study, 25 differently expressed IncRNAs were found to be independent prognosis factors for HNSCC. A recent study found over-expression of LINC01963 in pancreatic carcinoma cells inhibited proliferation of pancreatic cells via the miR-641/TMEFF2 pathway [26]. Up-regulated expression of LINC01980 in esophageal squamous cell carcinoma confers poor prognosis and as well promotes epithelial-mesenchymal transition (EMT) via the miR-190a-5p and MYO5A pathways [27]. In a related study, IncRNA AATBC was found to be over-expressed in NPC, corresponding to poor survival. Over-expression of IncRNA AATBC also promoted migration and invasion of NPC cells, mediated by miR-1237-3p [28]. IncRNA ELF3-antisense RNA 1 (ELF3-AS1) promotes the proliferation of oral squamous cell carcinoma (OSCC) cells by disrupting glucose metabolism. Overall, over-expression of ELF3-AS1 conferred poor OS of OSCC patients [29, 30]. Similarly, one recent study reported that AL161431.1 target and binds miR-1252-5p, inhibiting MAPK signaling in endometrial carcinoma cells [31]. PSMA3-AS1 knockdown suppresses the migration, proliferation and invasion of glioma cells in vivo and in vitro and represses proteasome inhibitors [32, 33]. Expression of PCED1B-AS1, closely associated with larger tumor size, higher grade, poor survival, rapid proliferation, glucose uptake and lactate release in cancer cells, was found to be upregulated in glioblastoma cells and tissues [34]. Paired box 8 antisense RNA 1 (PAX8-AS1) polymorphisms rs4848320 and rs6726151 are risk factor for the development of childhood acute lymphoblastic leukemia, but decreases the risk of developing cervical cancer [35, 36]. On the other hand, one study reported that down-regulation of AL450992.2 was associated with autoimmune disorders [37]. However, to date, there is no study on the role of ferroptosis-associated IncRNAs in the prognosis of HNSCC. Such findings may provide invaluable sight into the future control of cancers.

Here, the differently expressed ferroptosis-associated IncRNAs were stratified into two categories of high- and low-risk to explore their potential roles in HNSCC. Ferroptosis combined with immune checkpoint inhibitors (ICIs) synergistically enhance antitumor activity, even in ICI-resistant types [38]. There are currently very few studies exploring the relationship between ICI and ferroptosis. Increasing evidence suggests that microRNA (miRNA) and IncRNA are critical in mediating the regulation of ferroptosis. Nrf2 inhibits iron absorption, reducing production of ROS. As such, miRNA disrupt ferroptosis by regulating the expression of Nrf2 [39-41]. Meanwhile, miRNA participates in regulating transport, storage, utilization and absorption of iron. In recent years, new ferroptosis regulatory factors such as P53, ATF3/4, SLC7A11, ACSL4 and BECN1 pathway have been
discovered. Intriguingly, lncRNA plays a critical role in regulating the expression of these factors [42].

Ferroptosis is a new form of cell death that can potentially provide a new approach in tumor treatment. However, many key issues such as the interconnection between ferroptosis and other cell deaths and host immunogenicity remain unsolved. Thus, this study explored ferroptosis biomarkers useful in predicting the prognosis of HNSCC, which can inform treatment modalities for the diseases. Nonetheless, our signature profiles need further validation using different cohorts. Given that our findings were not validated using clinical samples, the reliability of our results cannot be fully guaranteed. Also, based on the limited clinical data, our findings should be applied with caution. In general, the prognostic prediction model developed in this study needs further validation.

Conclusion

Specific ferroptosis associated lncRNAs can predict the prognosis of HNSCC.

Abbreviations

HNSCC: Head and neck squamous cell carcinoma; ROS: reactive oxygen species; miRNA: microRNA; OS: overall survival (OS); DEGs: differentially expressed genes; TCGA: The Cancer Genome Atlas; GO: Gene ontology; BP: biological processes; MF: molecular function; CC: cellular components; KEGG: Kyoto Encyclopedia of Genes and Genomes; GSEA: Gene set enrichment analyses; FDR: false discovery rate; ssGSEA: single-sample gene set enrichment analysis (ssGSEA).

Supplementary Material

Supplementary tables. http://www.ijbs.com/v17p0702s1.xlsx

Authors’ contributions

W.Z.H. designed and analyzed the research study; W.Z.H. wrote and revised the manuscript, T.Y.; L.C. and Z.Y.J. collected and analysis the data and all authors have read and approved the manuscript.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Fang XN, Yin M, Li H, Liang C, Xu C, Yang GW, et al. Comprehensive analysis of competitive endogenous RNAs network associated with head and neck squamous cell carcinoma. Sci Rep. 2018; 8(1):10544.
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5):ES59-86.
3. Huang Y, Liu Z, Zhong L, Wen Y, Ye Q, Cao D, et al. Construction of an 11-microRNA-based signature and a prognostic nomogram to predict the overall survival of head and neck squamous cell carcinoma patients. BMC Genomics. 2020; 21(1):691.
4. Hitt M M, Alliday M J, Hara T. EBV gene expression in an NPC-related tumour. Embo Journal. 1989; 8(9):2639-2650.
5. Posner M, Vermorken JB. Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer. Semin Oncol. 2006; 33(5):221-8.
6. Kumpficz C, Moisls-Eichinger C, Pock J, Thurmer D, Wolf A. Preliminary insights into the impact of primary radiochemotherapy on the salivary microbiome in head and neck squamous cell carcinoma. Sci Rep. 2020; 10(1):16582.
7. Sung ES, Kim JY, Ahn YT, Lee IW, Choi SW, Jang HB, et al. An WG. Melatonin Exerts Anticancer Effects in Human Tongue Squamous Cell Carcinoma Cells by Promoting Autophagy. Anticancer Res. 2020; 40(11):8309-8317.
8. Huang L, McClatchy DB, Maher P, Liang Z, Diedrich JK, Soriano-Castell D, et al. Intracellular amyloid toxicity induces oxysis/ferroptosis regulated cell death. Cell Death Dis. 2020; 11(10):828.
9. Zhou N, Bao J, FerrDb: a manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations. Database (Oxford). 2020; 2020:bbaa021.
10. Newman AM, Li CL, Green MR. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):433-47.
11. Charoentong P, Finotello F, Angiolda M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer Immunogenomic Analyses Reveal Genotypic-Immunophenotypic Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep. 2017; 18(1):246-262.
12. Yoshiihara K, Shahnamadgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Infering tumor puberty and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612.
13. Shi J, Jiang D, Yang S, Zhang X, Wang J, Liu Y, et al. LPAR1, Correlated With LncRNA ZFAS1 promotes lung fibroblast-to-myofibroblast transition and ferroptosis via functioning as a ceRNA through miR-150-5p/SLC38A1 axis. Aging (Albany NY). 2020; 12(10):9085-9102.
14. Zhou N, Bao J, FerrDb: a manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations. Database (Oxford). 2020; 2020:bbaa021.
15. Newman AM, Li CL, Green MR. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):433-47.
16. Charoentong P, Finotello F, Angiolda M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer Immunogenomic Analyses Reveal Genotypic-Immunophenotypic Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep. 2017; 18(1):246-262.
17. Yoshiihara K, Shahnamadgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Infering tumor puberty and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612.
18. Shi J, Jiang D, Yang S, Zhang X, Wang J, Liu Y, et al. LPAR1, Correlated With LncRNA ZFAS1 promotes lung fibroblast-to-myofibroblast transition and ferroptosis via functioning as a ceRNA through miR-150-5p/SLC38A1 axis. Aging (Albany NY). 2020; 12(10):9085-9102.
Gu ZR, Liu W. The LncRNA AL161431.1 targets miR-1252-5p and facilitates cellular proliferation and migration via MAPK signaling in endometrial carcinoma. Eur Rev Med Pharmacol Sci. 2020; 24(5):2294-2302.

Zhou LI, Zhang M, Zhang YZ, Sun MF. Long non-coding RNA PSMA3-AS1 enhances cell proliferation and invasion by regulating miR-302a-3p/RAB22A in glioma. Biosci Rep. 2020; 40(9):BSR20191571.

Xu H, Han H, Song S, Yi N, Qian C, Qiu Y, et al. Exosome-Transmitted PSMA3 and PSMA3-AS1 Promote Proteasome Inhibitor Resistance in Multiple Myeloma. Clin Cancer Res. 2019; 25(6):1923-1935.

Zhou LL, Zhang M, Zhang YZ, Sun MF. Long non-coding RNA PSMA3-AS1 enhances cell proliferation, migration and invasion by regulating miR-302a-3p/RAB22A in glioma. Biosci Rep. 2020; 40(9):BSR20191571.

Xu H, Han H, Song S, Yi N, Qian C, Qiu Y, et al. Exosome-Transmitted PSMA3 and PSMA3-AS1 Promote Proteasome Inhibitor Resistance in Multiple Myeloma. Clin Cancer Res. 2019; 25(6):1923-1935.

Yao Z, Zhang Q, Guo F, Guo S, Yang B, Liu B, et al. Long Noncoding RNA PCED1B-AS1 Promotes the Warburg Effect and Tumorigenesis by Regulating HIF-1alpha in Glioblastoma. Cell Transplant. 2020; 29:963689219606777.

Bahari G, Hashemi M, Naderi M, Sadeghi-Bojd S, Taheri M. Long non-coding RNA PAX8-AS1 polymorphisms increase the risk of childhood acute lymphoblastic leukemia. Biomed Rep. 2018; 6(2):184-190.

Han J, Zhou W, Jia M, Wen J, Jiang J, Shi J, et al. Expression quantitative trait loci in long non-coding RNA PAX8-AS1 are associated with decreased risk of cervical cancer. Mol Genet Genomics. 2016; 291(4):1743-8.

Teimouri S, Hosseini A, Rezaenasab A, Ghaedi K, Ghoveidi E, Etemadifar M, et al. Integrative Analysis of lncRNAs in Th17 Cell Lineage to Discover New Potential Biomarkers and Therapeutic Targets in Autoimmune Diseases. Mol Ther Nucleic Acids. 2018; 12:393-404.

Kabaria S, Choi DC, Chaudhuri AD. MicroRNA-7 activates Nrf2 pathway by targeting Keap1 expression. Free Radic Biol Med. 2015; 89:548-556.

Yang M, Yao Y, Eades G, Zhang Y, Zhou Q. MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism. Breast Cancer Res Treat. 2011 Oct; 129(3):983-91.

Xu D, Zhu H, Wang C, Zhu X, Liu G, Chen C. microRNA-455 targets culin 3 to activate Nrf2 signaling and protect human osteoblasts from hydrogen peroxide. Oncotarget. 2017 Jul 22; 8(35):59225-59234.

Song X, Long D. Nrf2 and Ferroptosis: A New Research Direction for Neurodegenerative Diseases. Front Neurosci. 2020; 14:267.